

# ● PRINTER RUSH ●

(PTO ASSISTANCE)

Application : <u>09/724481</u>	Examiner : <u>Romeo</u>	GAU : <u>1647</u>
From : <u>PAP</u>	Location : <u>(IDC) FMF FDC</u>	Date : <u>4/15/05</u>
Tracking # : <u>06073359</u>		Week Date : <u>1/31/05</u>

DOC CODE	DOC DATE	MISCELLANEOUS
<input type="checkbox"/> 1449	_____	<input type="checkbox"/> Continuing Data
<input type="checkbox"/> IDS	_____	<input type="checkbox"/> Foreign Priority
<input type="checkbox"/> CLM	_____	<input type="checkbox"/> Document Legibility
<input type="checkbox"/> IIFW	_____	<input type="checkbox"/> Fees
<input type="checkbox"/> SRFW	_____	<input type="checkbox"/> Other
<input checked="" type="checkbox"/> DRW	<u>11/28/2000</u>	
<input type="checkbox"/> OATH	_____	
<input type="checkbox"/> 312	_____	
<input type="checkbox"/> SPEC	_____	

*Attention: Chief Draftsman*

[RUSH] MESSAGE: Please provide a new set of drawing sheets. The FIG. number label is placed in a location that causes the drawing to be read upside down in many of the figures.

\_\_\_\_\_

\_\_\_\_\_

*Thank you*

[XRUSH] RESPONSE: \_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_


\_\_\_\_\_

INITIALS: CB/R

NOTE: This form will be included as part of the official USPTO record, with the Response document coded as XRUSH.  
REV 10/04

# Effect of IGF-I Treatment on Total IGF-I

(Mean  $\pm$  SE)




Treatment Visits (Week)

FIG. 42

# Effect of IGF-I Treatment on IGF-II

(Mean  $\pm$  SE)




Treatment Visits (Week)

FIG. 43

# Effect of IGF-I Treatment on IGFBP-3

(Mean  $\pm$  SE)



Treatment Visits (Week)

FIG. 44